Choice of first-line antiretroviral therapy regimen and treatment outcomes for HIV in a middle income compared to a high income country: a cohort study

[1]  C. Leen,et al.  British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2015 , 2016, HIV medicine.

[2]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[3]  A. d’Arminio Monforte,et al.  Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort , 2014, Journal of the International AIDS Society.

[4]  N. Ford,et al.  CD4+ T-cell recovery after initiation of antiretroviral therapy in a resource-limited setting: A prospective cohort analysis , 2014, Antiviral therapy.

[5]  A. Pacheco,et al.  Changing Mortality Profile among HIV-Infected Patients in Rio de Janeiro, Brazil: Shifting from AIDS to Non-AIDS Related Conditions in the HAART Era , 2013, PloS one.

[6]  A. Mocroft,et al.  CD4 count and viral load specific rates of AIDS, non‐AIDS and deaths according to current antiretroviral use , 2012, AIDS.

[7]  A. Mocroft,et al.  Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study , 2012, BMC Infectious Diseases.

[8]  C. Leen,et al.  7.0 Managing virological failure , 2012, HIV medicine.

[9]  A. Mocroft,et al.  Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study , 2012, PLoS ONE.

[10]  C. Yiannoutsos,et al.  Mortality Associated With Discordant Responses to Antiretroviral Therapy in Resource-Constrained Settings , 2010, Journal of acquired immune deficiency syndromes.

[11]  M. Youle,et al.  Comparison of Nucleoside Reverse Transcriptase Inhibitor Use as Part of First-Line Therapy in a Serbian and a UK HIV Clinic , 2009, HIV clinical trials.

[12]  J. Sterne,et al.  Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies , 2007, AIDS.

[13]  J. Lang,et al.  Virologic Response of Zidovudine, Lamivudine, and Tenofovir Disoproxil Fumarate Combination in Antiretroviral-Naive HIV-1-Infected Patients , 2006, Journal of acquired immune deficiency syndromes.

[14]  John T Brooks,et al.  Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study , 2006, Journal of acquired immune deficiency syndromes.

[15]  M. Egger,et al.  Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. , 2005, International journal of epidemiology.

[16]  B. Gazzard.  British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008 , 2005, HIV medicine.

[17]  M. Youle,et al.  An audit of antiretroviral treatment use in HIV‐infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use , 2003, HIV medicine.

[18]  M. Moroni,et al.  Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients , 2000, AIDS.

[19]  M J Daniels,et al.  CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta‐analysis of studies of the AIDS Clinical Trials Group , 1998, AIDS.

[20]  Md Pgy Yury Parra.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection: The INSIGHT START Study Group , 2016 .

[21]  S. Hammer,et al.  Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. , 1998, Journal of Infectious Diseases.